New York, October 16, 2016 -- Moody's Investors Service has assigned an overall covenant quality score of 4.39 to Horizon Pharma, Inc.'s$300m _% Senior Notes due 2024. Subscribers can read the full report at: http://www.moodys.com/viewresearchdoc.aspx?docid=PBC_1046315.

Vollständigen Artikel bei Moodys lesen